Browse the corpus

Neurokinin-1 (NK-1) receptor antagonists are antiemetic drugs with unique anxiolytic, antidepressant, and antiemetic properties. The discovery of NK-1 receptor blockers was crucial in preventing emesis associated with cancer chemotherapy. The NK-1 receptor antagonist competitively binds to the NK-1 receptor, thereby blocking the binding of substance P and preventing the transmission of the emetic signal. This activity reviews the indications, contraindications, mechanism of action, adverse event profile, and other crucial aspects of antiemetic NK-1 receptor blockers within the clinical setting. This activity also focuses on essential information required by members of an interprofessional team responsible for treating patients who stand to benefit therapeutically from these agents. Objectives: Identify appropriate candidates for neurokinin-1 receptor antagonists based on their understanding of the patient's chemotherapy regimen and emetogenic risk. Apply knowledge of neurokinin-1 receptor antagonists in diverse clinical scenarios, tailoring treatment approaches to individual patient needs and characteristics. Select the most appropriate neurokinin-1 receptor antagonist based on patient-specific factors, treatment goals, and potential drug interactions. Collaborate with other interprofessional healthcare teams, such as pharmacists and nurses, optimizing the use of neurokinin-1 receptor antagonists to achieve the best outcomes in managing chemotherapy-induced nausea and vomiting. Access free multiple choice questions on this topic.

Symptoms of an overdose of NK-1 receptor antagonists may include drowsiness and headache. Although aprepitant is associated with increased serum liver enzyme during therapy, a verified correlation between clinically specific liver injury cases and jaundice has not been established. Serum aminotransferase elevations during aprepitant therapy were observed in 6% of treated patients compared to 4.3% of controls receiving cancer chemotherapy. These elevations were generally mild to moderate, transient, and, in some cases, asymptomatic without jaundice. Published cases of clinically significant liver injury attributable to aprepitant are not convincingly documented in the literature. As a result, significant liver injury from aprepitant or fosaprepitant would be exceedingly rare.[10]

NK-1 receptor antagonists prove highly effective in managing nausea and vomiting induced by various factors. Despite their safety and efficacy, these drugs are prohibitively expensive and only used in hospital settings. Hospital pharmacists frequently receive alerts when physicians prescribe these drugs, prompting the ordering clinician to request a more cost-effective yet equally efficacious alternative.[17][18] To mitigate the impact on healthcare expenses, a committee comprising physicians, advanced practice practitioners, pharmacists, and hospital administrators should collaborate to formulate practice guidelines for utilizing these medications in hospital settings. The elevated cost of these drugs frequently renders them financially inaccessible for many patient populations, necessitating the implementation of special programs.[19] To achieve therapeutic coherence, the interprofessional healthcare team must be in sync and work together toward a common goal. Given the significant drug interactions associated with NK-1 receptor antagonists, it is imperative for pharmacists to engage in communication with the ordering clinician whenever potential drug interactions could impact the effectiveness of the patient's therapeutic regimen, as mentioned above. Similarly, nursing staff should be well-informed about proper drug administration and can consult with the pharmacist or physician regarding any concerns. Nurses are in an ideal position to monitor the effectiveness of treatments and identify any adverse reactions. They should promptly report any issues to the clinician who ordered the treatment. NK-1 receptor antagonists can be essential for oncologists, oncology-specialized nurses, and pharmacists in addressing chemotherapy-related nausea. These instances underscore the importance of adopting an interprofessional team approach to NK-1 receptor antagonist therapy, ensuring the delivery of maximum therapeutic efficacy while minimizing adverse events and drug interactions.